Author:
Salama Khalid M.,Abo Ragab Hesham M.,El Sherbiny Mohammed F.,Morsi Ali A.,Souidan Ibrahim I.
Publisher
Springer Science and Business Media LLC
Subject
Obstetrics and Gynaecology,Reproductive Medicine,General Medicine
Reference32 articles.
1. Tang H, Mourad S, Zhai SD, Hart RJ. Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2016;11:CD008605.
2. Ashrafi M, Bahmanabadi A, Akhond MR, Arabipoor A. Predictive factors of early moderate/severe ovarian hyperstimulation syndrome in non-polycystic ovarian syndrome patients: a statistical model. Arch Gynecol Obstet. 2015;292(5):1145–52.
3. Kdous M, M'Solly S, Zhioua F, Meriah S. Use of GnRh antagonist (Cetrorelix) in controlled ovarian hyperstimulation in women with polycystic ovary disease. Tunis Med. 2008;86(12):1060–5.
4. Martínez F, Clua E, Santmartí P, Boada M, Rodriguez I, Coroleu B. Randomized, comparative pilot study of pituitary suppression with depot leuprorelin versus cetrorelix acetate 3 mg in gonadotropin stimulation protocols for oocyte donors. Fertil Steril. 2010;94(6):2433–6.
5. Depalo R, Jayakrishan K, Garruti G, Totaro I, Panzarino M, Giorgino F. GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET). Reprod Biol Endocrinol. 2012;10:26.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献